Wellmatix
Category: AI in Biotech / Drug Discovery
An AI-powered SaaS platform that accelerates new materials and drug discovery by integrating patents, academic papers, and physics-based simulation data to propose optimal candidate materials in early development stages. Wellmatix was founded in 2024. The company is led by Aichi Shatiyabrata (James Kang). Based in Busan, South Korea. Team size: 11-50. Total funding raised: $35,600. Latest round: Seed. Key investors include Startupbootcamp Singapore, Busan Creative Economy Innovation Center, MIT DesignX.
- Founded
- 2024
- Headquarters
- Busan, South Korea
- Team size
- 11-50
- Total funding
- $35,600
Value proposition
Reduces material development timeline from 7 years to 1 year while significantly cutting R&D costs, using AI engines trained on patents, academic papers, and physics-based simulation data to propose candidate materials in early development stages.
Products and solutions
AI Materials Discovery Platform, Drug Discovery Platform, Deep Learning Material Behavior Prediction System, Physics-based Simulation Integration Module, Unified R&D Workflow Optimization System
Unique value
First-mover in Korea integrating patents, academic papers, and physics-based simulation data into a unified AI engine for materials discovery. Combines reinforcement learning (RL) and graph neural networks (GNN) to predict material behaviors in real-time with high accuracy.
Target customer
R&D departments in materials science companies, semiconductor manufacturers, battery developers, water treatment companies, pharmaceutical firms, and packaging material producers
Industries served
Carbon Capture, Battery & Energy Storage, Semiconductors, Water Treatment, Pharmaceuticals, Packaging Materials
Technology advantage
Proprietary AI framework that seamlessly connects formulation, characterization, and scale-up processes in a unified workflow. Demonstrated ability to reduce carbon capture material development from 7 years to 1 year in PoC, achieving 7x acceleration compared to traditional trial-and-error approaches.
How they differentiate
First-mover in Korea integrating patents, academic papers, and physics-based simulation data into unified AI engine. Combines reinforcement learning (RL) and graph neural networks (GNN) for real-time material behavior prediction. Demonstrated 7x acceleration in development timeline (7 years to 1 year) in carbon capture PoC. Focuses on both materials discovery and drug discovery platforms.
Main competitors
Citrine Informatics, Schrödinger, Polymerize
Key partnerships
SilTest (Germany) - MOU signed for semiconductor materials development, Finnish water treatment company - Active PoC collaboration, French flexible electronics material company - Contract signed, Startupbootcamp Singapore - Strategic investor with 8% equity in Singapore subsidiary, Busan Creative Economy Innovation Center - Incubation support, Global Startup School - Founding support program, Panasonic - IP collaboration through IPHatch program
Notable customers
SilTest (Germany) - Semiconductor company, Finnish water treatment company (PoC ongoing), French flexible electronics material company, Panasonic (through IPHatch program)
Major milestones
Won 2nd place at MIT DesignX (30,000 AED, 2025), Raised €25,000 from Startupbootcamp Singapore for 8% of Singapore subsidiary (Feb 2026), Established Singapore subsidiary (2026), Selected for IPHatch / Panasonic IP collaboration, MOU with SilTest (Germany), Carbon capture PoC with 7x acceleration, EriCa Reactor cohort 1; established Finnish entity at EriCa Green Chemistry Park, Espoo (summer 2026), Selected for Helsinki Health Incubator (HHI) 2026, MOU with Korea Basic Science Institute (KBSI), MOU with IIT Madras Dept. of Biotechnology, Collaboration with Madras Pharmaceuticals, Federated learning ADMET platform beta launch (applications close Sep 10 2026)
Growth metrics
Singapore subsidiary (2026); Finnish/EU entity at EriCa Green Chemistry Park Espoo (summer 2026); PoCs with 7x materials R&D acceleration; expanding drug-discovery GTM (federated ADMET beta, AI-generated candidates for cancer/Parkinson’s); MoUs with KBSI and IIT Madras; LinkedIn company size 11-50
Market positioning
Early-stage AI materials discovery startup with regional advantage in Korean market, expanding globally through strategic partnerships in Europe and Asia-Pacific. Positioned as comprehensive SaaS platform serving R&D departments across multiple industries.
Geographic focus
South Korea (Busan HQ), Singapore subsidiary, Finland/EU base at EriCa Green Chemistry Park (Espoo, entity established summer 2026); active partnerships/PoCs in Germany, Finland, France; expanding Middle East and broader Europe
Patents and IP
Selected for IPHatch program for Panasonic patent collaboration, indicating access to established IP portfolio. No independently registered patents disclosed as of latest update.
About Aichi Shatiyabrata (James Kang)
Indian-born entrepreneur who obtained Korean citizenship in 2025. Founded AI-based new material design company after receiving support from Global Startup School and Busan Creative Economy Innovation Center. Has experience applying AI research to industrial applications, specifically focusing on reducing time and costs in material development from 7 years to 1 year.
More AI in Biotech / Drug Discovery companies
Official website: https://well-matix.com